logo-loader
viewSummit Therapeutics PLC

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole progress

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan.

The investment will help get the company’s next-generation antibiotic through phase III clinical trials.

Edwards will be adding the role of chairman to his responsibilities as chief executive.

Quick facts: Summit Therapeutics PLC

Price: 20.8 GBX

AIM:SUMM
Market: AIM
Market Cap: £69.92 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics 'taking leadership role' in development of new antibiotics

Summit Therapeutics PLC's (LON:SUMM) Dr Richard Pye speaks to Proactive London's Andrew Scott following a first quarter update on operational progress across the portfolio. Summit's currently developing three flagship treatments; Ridinilazole, designed to treat Clostridium difficile which...

on 13/6/19

2 min read